Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Tetraphase Pharmaceuticals Inc. (TTPH) Message Board

A Look at Tetraphase Pharmaceuticals’ Target Mar

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 31
(Total Views: 407)
Posted On: 04/19/2018 8:10:40 AM
Avatar
Posted By: jonny_red32
A Look at Tetraphase Pharmaceuticals’ Target Market

Eravacycline
Tetraphase Pharmaceuticals ( $TTPH ) is developing eravacycline, a fully synthetic flurocycline for use as a first-line empiric monotherapy for treating multidrug-resistant infections. These infections include gram-negative infections such as those found in complicated intra-abdominal infections (or cIAL).

Tetraphase Pharmaceuticals conducted IGNITE, a global Phase 3 clinical trial program for eravacycline. The company announced top-line data from the IGNITE4 trial in July 2017, comparing eravacycline with meropenem for treating cIAL in 500 patients. Eravacycline met the primary endpoint of statistical non-inferiority of clinical response.



Tetraphase Pharmaceuticals submitted a New Drug Application (or NDA) to the FDA for intravenous eravacycline on January 2, 2018. The FDA has set a target date of August 28, 2018, under the Prescription Drug User Fee Act (or PDUFA). The company also submitted a marketing authorization application (or MAA) to the EMA in 3Q17 for intravenous eravacycline for treating cIAL. The drug has received qualified infectious disease product (or QIDP) and fast track designation by the FDA.


Drug-resistant antibiotic market
Antibiotics are commonly prescribed for treating patients with acute and chronic infectious disease. Factors such as inappropriate use of antibiotics and the lack of new therapies have resulted in an accelerated increase in bacterial infections that have high resistance to antibacterial agents.

According to an analysis commissioned by the UK government in 2016, global microbial resistance—including bacteria, viruses, and fungi—results in at least 700,000 deaths each year. The report estimated that failing to develop effective treatments by 2050 could lead to 10.0 million additional deaths per year.

In a 2013 report, the Centers for Disease Control (or CDC) estimated that every year, more than 2.0 million people acquire serious infections that are resistant to antibiotics. The total cost of these infections to the US economy is estimated to be ~$20.0 billion above and beyond direct healthcare costs.

In the next part of this series, we’ll look at Tetraphase Pharmaceuticals’ financial performance.


(0)
(0)




Tetraphase Pharmaceuticals Inc. (TTPH) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  


Engineer by trade & Swing Trader at Heart!

Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW


CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment










Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us